EA201690559A1 - Способы определения ответа на терапию - Google Patents

Способы определения ответа на терапию

Info

Publication number
EA201690559A1
EA201690559A1 EA201690559A EA201690559A EA201690559A1 EA 201690559 A1 EA201690559 A1 EA 201690559A1 EA 201690559 A EA201690559 A EA 201690559A EA 201690559 A EA201690559 A EA 201690559A EA 201690559 A1 EA201690559 A1 EA 201690559A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapy
response
determining
methods
metadoxine
Prior art date
Application number
EA201690559A
Other languages
English (en)
Inventor
Ярон Дэниели
Йоханна Шуманн
Джонатан Рубин
Original Assignee
Алкобра Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Алкобра Лтд. filed Critical Алкобра Лтд.
Publication of EA201690559A1 publication Critical patent/EA201690559A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение в основном относится к способам определения ответа на терапию метадоксином для лечения синдрома ломкой Х-хромосомы и других когнитивных нарушений. Изобретение также относится к идентификации индивидуумов, которые могут отвечать на терапию метадоксином.
EA201690559A 2013-09-09 2014-09-09 Способы определения ответа на терапию EA201690559A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
PCT/US2014/054816 WO2015035402A1 (en) 2013-09-09 2014-09-09 Methods of determining response to therapy

Publications (1)

Publication Number Publication Date
EA201690559A1 true EA201690559A1 (ru) 2016-08-31

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690557A EA201690557A1 (ru) 2013-09-09 2014-09-09 Способы лечения синдрома ломкой х-хромосомы и связанных расстройств
EA201690559A EA201690559A1 (ru) 2013-09-09 2014-09-09 Способы определения ответа на терапию

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690557A EA201690557A1 (ru) 2013-09-09 2014-09-09 Способы лечения синдрома ломкой х-хромосомы и связанных расстройств

Country Status (12)

Country Link
EP (2) EP3044589A1 (ru)
JP (2) JP2016530291A (ru)
KR (2) KR20160078956A (ru)
CN (2) CN105917225A (ru)
AU (2) AU2014316779A1 (ru)
CA (2) CA2922901A1 (ru)
EA (2) EA201690557A1 (ru)
IL (2) IL244343A0 (ru)
MX (2) MX2016003006A (ru)
SG (2) SG11201601830PA (ru)
TW (2) TW201606304A (ru)
WO (2) WO2015035402A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9673408B2 (en) * 2013-07-31 2017-06-06 Udc Ireland Limited Luminescent diazabenzimidazole carbene metal complexes
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
WO2019197632A1 (en) * 2018-04-13 2019-10-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
AU2019280980A1 (en) * 2018-06-07 2021-01-07 Ovid Therapeutics Inc. Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
JP7412583B2 (ja) * 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EP2445498A1 (en) * 2009-06-25 2012-05-02 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition

Also Published As

Publication number Publication date
IL244343A0 (en) 2016-04-21
WO2015033224A3 (en) 2015-07-02
SG11201601605YA (en) 2016-04-28
TW201605443A (zh) 2016-02-16
CA2922901A1 (en) 2015-03-12
MX2016003002A (es) 2016-09-08
WO2015033224A2 (en) 2015-03-12
AU2014315026A1 (en) 2016-03-24
KR20160086818A (ko) 2016-07-20
WO2015035402A1 (en) 2015-03-12
CN105517546A (zh) 2016-04-20
CN105917225A (zh) 2016-08-31
SG11201601830PA (en) 2016-04-28
EA201690557A1 (ru) 2016-07-29
JP2016530291A (ja) 2016-09-29
MX2016003006A (es) 2016-06-10
EP3043792A2 (en) 2016-07-20
KR20160078956A (ko) 2016-07-05
TW201606304A (zh) 2016-02-16
CA2923421A1 (en) 2015-03-12
AU2014316779A1 (en) 2016-03-17
EP3044589A1 (en) 2016-07-20
IL244453A0 (en) 2016-04-21
JP2016530536A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
EA201690559A1 (ru) Способы определения ответа на терапию
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
PH12019500408A1 (en) Asid-alpha glucosidase variants and uses thereof
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EA201691991A1 (ru) Мультиспецифические антитела
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
PH12019500376A1 (en) Acid-alpha glucosidase variants and uses thereof
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
IN2014DN05885A (ru)
EA201691314A1 (ru) Терапевтические способы и композиции
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.